{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:40:59Z","timestamp":1791931259890,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Axillary lymph node dissection (ALND) is associated with significant morbidity in breast cancer patients. In HER2-positive (HER2+) breast cancer, neoadjuvant chemotherapy (NAC) combined with anti-HER2 therapy can achieve high rates of pathological complete response (pCR), supporting the de-escalation of axillary surgery. Identifying reliable predictors of axillary pCR is essential for safely omitting ALND in selected patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included 60 women with HER2+ breast cancer and axillary involvement treated with NAC followed by surgery between 2015 and 2022. All patients had pre- and post-treatment mammography, ultrasound, and MRI. The variables analyzed included age, Ki-67 index, hormone receptor status, breast and axillary radiological and pathological response (rCR, pCR), number of suspicious lymph nodes, and type of axillary surgery. Univariate and multivariate logistic regression models were performed to identify independent predictors of axillary pCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Axillary pCR was achieved in 85% of patients. On univariate analysis, axillary rCR (OR\u2009=\u20095.83; 95% CI: 1.30\u201326.12;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021) and breast rCR (OR\u2009=\u20096.79; 95% CI: 1.27\u201336.34;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025) were significantly associated with axillary pCR. Multivariate analysis identified axillary rCR (OR\u2009=\u200917.98; 95% CI: 1.43\u2013225.93;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.025) and Ki-67 index (OR\u2009=\u20090.90; 95% CI: 0.82\u20130.99;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045) as independent predictors of axillary pCR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Axillary rCR and Ki-67 are independent predictors of axillary pCR in HER2+ breast cancer patients treated with NAC. These findings may help optimize axillary management and support less invasive approaches. Further multicenter studies should validate predictive models and refine imaging criteria for axillary response assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Question<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Identifying predictive factors for axillary pCR in HER2+ breast cancer patients undergoing NAC<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Findings<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Axillary radiological complete response predicted axillary pCR in univariate (p\u2009=\u20090.021) and multivariate analyses (p\u2009=\u20090.025), while Ki-67 was marginally significant in the multivariate model (p\u2009=\u20090.045)<\/jats:italic>\n                      .\n                    <\/jats:p>\n                    <jats:p>\n                      <jats:bold>\n                        <jats:italic>Clinical relevance<\/jats:italic>\n                      <\/jats:bold>\n                      <jats:italic>Recognizing reliable predictors of axillary pCR may support the omission of ALND in selected HER2+ patients, minimizing surgical morbidity<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-025-12241-5","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T11:52:59Z","timestamp":1766577179000},"page":"3367-3377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Predictive factors of axillary pathological complete response in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1753-719X","authenticated-orcid":false,"given":"Marta","family":"Rodr\u00edguez de Trujillo Campo-Coss\u00edo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Romero-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Rodr\u00edguez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Font-Ugalde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Raya-Povedano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"\u00c1lvarez-Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"12241_CR1","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa022152","volume":"347","author":"B Fisher","year":"2002","unstructured":"Fisher B, Anderson S, Bryant J et al (2002) Twenty-year follow-up of a randomized clinical trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347:1233\u20131241","journal-title":"N Engl J Med"},{"key":"12241_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1093\/qjmed\/hci053","volume":"98","author":"B Clark","year":"2005","unstructured":"Clark B, Sitzia J, Harlow W (2005) Incidence and risk of arm oedema following treatment for breast cancer: a three-year follow-up study. QJM 98:343\u2013348","journal-title":"QJM"},{"key":"12241_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG)","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"12241_CR4","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1056\/NEJM199810013391401","volume":"339","author":"D Krag","year":"1998","unstructured":"Krag D, Weaver D, Alex JC, Fairbank JT (1998) The sentinel node in breast cancer\u2014a multicenter validation study. N Engl J Med 339:941\u2013946","journal-title":"N Engl J Med"},{"key":"12241_CR5","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa012782","volume":"349","author":"U Veronesi","year":"2003","unstructured":"Veronesi U, Paganelli G, Viale G et al (2003) A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 349:546\u2013553","journal-title":"N Engl J Med"},{"key":"12241_CR6","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569\u2013575","journal-title":"JAMA"},{"key":"12241_CR7","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","volume":"273","author":"S Samiei","year":"2021","unstructured":"Samiei S, de Mooij CM, Lobbes MBI, Keymeulen KBMI, van Nijnatten TJA, Smidt ML (2021) Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis. Ann Surg 273:694\u2013700","journal-title":"Ann Surg"},{"key":"12241_CR8","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.3390\/curroncol30030215","volume":"30","author":"K Englander","year":"2023","unstructured":"Englander K, Chintapally N, Gallagher J et al (2023) Factors influencing lymph node positivity in HER2\/neu+ breast cancer patients. Curr Oncol 30:2825\u20132833","journal-title":"Curr Oncol"},{"key":"12241_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000502910","volume":"98","author":"N Fujita","year":"2020","unstructured":"Fujita N, Enomoto Y, Inakami K et al (2020) Prognostic factors in HER2-positive primary breast cancer patients treated using neoadjuvant chemotherapy plus trastuzumab. Oncology 98:35\u201341","journal-title":"Oncology"},{"key":"12241_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/cancers13030370","volume":"13","author":"E Laas","year":"2021","unstructured":"Laas E, Bresset A, F\u00e9ron JG et al (2021) HER2-positive breast cancer patients with pre-treatment axillary involvement or postmenopausal status benefit from neoadjuvant rather than adjuvant chemotherapy plus trastuzumab regimens. Cancers (Basel) 13:370","journal-title":"Cancers (Basel)"},{"key":"12241_CR11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH et al (2012) A study of neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer. N Engl J Med 366:109\u2013119","journal-title":"N Engl J Med"},{"key":"12241_CR12","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA et al (2013) Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA 310:1455\u20131461","journal-title":"JAMA"},{"key":"12241_CR13","first-page":"75","volume":"35","author":"L Bernet","year":"2022","unstructured":"Bernet L, Pi\u00f1ero A, Mart\u00ednez M, Vidal-Sicart S, Algara Lopez M, Palomares E (2022) Consenso de la Sociedad Espa\u00f1ola de Senolog\u00eda y Patolog\u00eda Mamaria (SESPM) sobre la biopsia selectiva del ganglio centinela (BSGC) y el manejo axilar en el c\u00e1ncer de mama (2022). Rev Senol Patol Mamaria 35:75\u201389","journal-title":"Rev Senol Patol Mamaria"},{"key":"12241_CR14","first-page":"770","volume":"151","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. JAMA Surg 151:770\u2013777","journal-title":"JAMA Surg"},{"key":"12241_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10549-020-05970-2","volume":"185","author":"A Garcia-Tejedor","year":"2021","unstructured":"Garcia-Tejedor A, Fernandez-Gonzalez S, Ortega R et al (2021) Can we avoid axillary lymph node dissection in N2 breast cancer patients with chemo-sensitive tumours such as HER2 and TNBC?. Breast Cancer Res Treat 185:657\u2013666","journal-title":"Breast Cancer Res Treat"},{"key":"12241_CR16","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.3390\/cancers15133325","volume":"15","author":"X Zhang","year":"2023","unstructured":"Zhang X, Sun X, Zhang Y et al (2023) Omission of sentinel lymph node biopsy after neoadjuvant systemic therapy in HER2+ and triple-negative breast cancer patients. Cancers (Basel) 15:3325","journal-title":"Cancers (Basel)"},{"key":"12241_CR17","doi-asserted-by":"publisher","first-page":"7098","DOI":"10.1200\/JCO.2005.11.124","volume":"23","author":"AM Gonz\u00e1lez-Angulo","year":"2005","unstructured":"Gonz\u00e1lez-Angulo AM, McGuire SE, Buchholz TA et al (2005) Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy. J Clin Oncol 23:7098\u20137141","journal-title":"J Clin Oncol"},{"key":"12241_CR18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2007.14.5565","volume":"26","author":"M Kyndi","year":"2008","unstructured":"Kyndi M, S\u00f8rensen FB, Knudsen H et al (2008) Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 26:1419\u20131426","journal-title":"J Clin Oncol"},{"key":"12241_CR19","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4274\/ejbh.galenos.2024.2024-3-8","volume":"20","author":"G Rais","year":"2024","unstructured":"Rais G, Mokfi R, Boutaggount F et al (2024) Assessment of the predictive role of Ki-67 in breast cancer patients\u2019 responses to neoadjuvant chemotherapy. Eur J Breast Health 20:199\u2013206","journal-title":"Eur J Breast Health"},{"key":"12241_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","volume":"293","author":"P Kumar","year":"2016","unstructured":"Kumar P, Aggarwal R (2016) An overview of triple-negative breast cancer. Arch Gynecol Obstet 293:247\u2013269","journal-title":"Arch Gynecol Obstet"},{"key":"12241_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-024-02500-5","volume":"24","author":"L Yilmaz","year":"2024","unstructured":"Yilmaz L, Kus T, Aytekin A, Aktas G, Uzun E, Maralcan G (2024) Prediction of the number of positive axillary lymph nodes according to sentinel lymph node involvement and biological subtypes in patients receiving neoadjuvant chemotherapy. BMC Surg 24:213","journal-title":"BMC Surg"},{"key":"12241_CR22","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/j.clbc.2024.03.005","volume":"24","author":"JX Huang","year":"2024","unstructured":"Huang JX, Chen YJ, Wang XY et al (2024) Nomogram based on US and clinicopathologic characteristics: axillary nodal evaluation following neoadjuvant chemotherapy in patients with node-positive breast cancer. Clin Breast Cancer 24:e452\u2013e463","journal-title":"Clin Breast Cancer"},{"key":"12241_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-024-07332-8","volume":"206","author":"D Brabender","year":"2024","unstructured":"Brabender D, Ballard A, Kim S, Hovanessian-Larsen L, Sener SF (2024) Use of ultrasound and MRI to stage the axilla for breast cancer before and after neoadjuvant chemotherapy prior to targeted sentinel lymphadenectomy. Breast Cancer Res Treat 206:595\u2013602","journal-title":"Breast Cancer Res Treat"},{"key":"12241_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.845823","volume":"12","author":"Z Li","year":"2022","unstructured":"Li Z, Tong Y, Chen X, Shen K (2022) Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients. Front Oncol 12:845823","journal-title":"Front Oncol"},{"key":"12241_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12957-023-03174-8","volume":"21","author":"N Pislar","year":"2023","unstructured":"Pislar N, Gasljevic G, Marolt Music M, Borstnar S, Zgajnar J, Perhavec A (2023) Axillary ultrasound for predicting response to neoadjuvant treatment in breast cancer patients\u2014a single institution experience. World J Surg Oncol 21:292","journal-title":"World J Surg Oncol"},{"key":"12241_CR26","doi-asserted-by":"crossref","first-page":"109792","DOI":"10.1016\/j.ejrad.2021.109792","volume":"141","author":"I Skarping","year":"2021","unstructured":"Skarping I, F\u00f6rnvik D, Zackrisson S, Borgquist S, Ryd\u00e9n L (2021) Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer. Eur J Radiol 141:109792","journal-title":"Eur J Radiol"},{"key":"12241_CR27","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"12241_CR28","doi-asserted-by":"publisher","first-page":"646","DOI":"10.2214\/AJR.07.2460","volume":"191","author":"DG Bedi","year":"2008","unstructured":"Bedi DG, Krishnamurthy R, Krishnamurthy S et al (2008) Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. AJR Am J Roentgenol 191:646\u2013652","journal-title":"AJR Am J Roentgenol"},{"key":"12241_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.suronc.2021.101629","volume":"38","author":"M Mart\u00ednez-G\u00e1lvez","year":"2021","unstructured":"Mart\u00ednez-G\u00e1lvez M, Flores-Funes D, Aguilar-Jim\u00e9nez J et al (2021) Development of a predictive score of axillary lymph node dissection based on targeted axillary dissection in patients with breast cancer diagnosis, affected lymph nodes, and neoadjuvant treatment. Surg Oncol 38:101629","journal-title":"Surg Oncol"},{"key":"12241_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J et al (2024) Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22:331\u2013357","journal-title":"J Natl Compr Canc Netw"},{"key":"12241_CR31","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/his.13880","volume":"75","author":"SCY Leung","year":"2019","unstructured":"Leung SCY, Nielsen TO, Zabaglo LA et al (2019) Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology 75:225\u2013235","journal-title":"Histopathology"},{"key":"12241_CR32","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","volume":"12","author":"KN Ogston","year":"2003","unstructured":"Ogston KN, Miller ID, Payne S et al (2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12:320\u2013327","journal-title":"Breast"},{"key":"12241_CR33","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","volume":"32","author":"HJ Burstein","year":"2021","unstructured":"Burstein HJ, Curigliano G, Th\u00fcrlimann B et al (2021) Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for the treatment of early breast cancer 2021. Ann Oncol 32:1216\u20131235","journal-title":"Ann Oncol"},{"key":"12241_CR34","first-page":"1934","volume":"25","author":"BL Smith","year":"2018","unstructured":"Smith BL, Gadd MA, Dirbas FM et al (2018) Predictors of axillary pathologic complete response after neoadjuvant chemotherapy in HER2-positive breast cancer. Ann Surg Oncol 25:1934\u20131940","journal-title":"Ann Surg Oncol"},{"key":"12241_CR35","first-page":"1809","volume":"26","author":"AR Johnson","year":"2020","unstructured":"Johnson AR, Zhao J, Yang F et al (2020) The role of radiologic complete response in predicting axillary pathological complete response in breast cancer patients. Breast J 26:1809\u20131815","journal-title":"Breast J"},{"key":"12241_CR36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4048\/jbc.2017.20.2.150","volume":"20","author":"H Lee","year":"2017","unstructured":"Lee H, Park S, Park HS et al (2017) Higher Ki-67 expression is associated with poor long-term prognosis in breast cancer patients who achieve a pathological complete response after neoadjuvant chemotherapy. J Breast Cancer 20:150\u2013157","journal-title":"J Breast Cancer"},{"key":"12241_CR37","doi-asserted-by":"crossref","unstructured":"Van Hemert AKE, van Loevezijn AA, Baas MSPD et al (2025) Omitting axillary lymph node dissection in breast cancer patients with extensive nodal disease and excellent response to primary systemic therapy using the MARI protocol. Breast 80:104411","DOI":"10.1016\/j.breast.2025.104411"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12241-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-025-12241-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-025-12241-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T15:47:05Z","timestamp":1786722425000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-025-12241-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["12241"],"URL":"https:\/\/doi.org\/10.1007\/s00330-025-12241-5","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The scientific guarantor of this publication is Marina \u00c1lvarez Benito.","order":1,"name":"Ethics","label":"Guarantor","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Pilar Font Ugalde has significant statistical expertise.","order":3,"name":"Ethics","label":"Statistics and biometry","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":4,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Institutional Review Board approval was obtained.","order":5,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study subjects have not been previously reported.","order":6,"name":"Ethics","label":"Study subjects or cohorts overlap","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"order":7,"name":"Ethics","label":"Methodology","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}